Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Parallel Clinical Trial

NCT02561078 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02561078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02561078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Parallel Clinical Trial
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
October 20, 2015
Completion date
May 9, 2017
Enrollment
420 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus